Dr. David R. Guyer, M.D., served as Advisor of Sound Pharmaceuticals, Inc. since April 13, 2017 until October 12, 2017. Dr. Guyer is a Consultant on Ophthalmic Products to more than 12 different pharmaceutical companies. He has been the Executive Chairman at Ophthotech Corporation since July 1, 2017 and has been its Executive Director since January 2007. He is a Co-Founder and Executive Chairman of Imagen Biotech, Inc. He Co-Founded Ophthotech Corporation and served as its Chief Executive Officer from April 2013 to July 1, 2017. He served as Scientific Advisor of Iconic Therapeutics Inc. He was a Venture Partner of SV Health Investors, LLC, which he joined in May 2006. He was a Partner at SV Health Investors, LLC and is focused on biotechnology. He co-founded Eyetech Pharmaceuticals Inc. and served as its Chief Executive Officer. Dr. Guyer was a Co-Founder of Oldtech Inc. and served as its Chief Executive Officer since February 2000. He served as a Consultant to management and the Board at OSI Pharmaceuticals, where he provides specialist input in ophthalmology and retinal disease. He served as Chief Executive Officer (OSI) Eyetech at OSI Pharmaceuticals Inc. from November 2005 to May 2006. He served as an Executive Vice President at OSI Pharmaceuticals Inc. from November 14, 2005 to May 2006. He serves as the Chairman of PanOptica Inc. He served as Chairman of Ophthotech Corporation since January 2007 until July 1, 2017. He served as Chairman at New York University College of Medicine. He served as the Chairman of Danube Pharmaceuticals Inc. since June 2008. He has been a Non-Executive Director of ThromboGenics NV since December 20, 2013 and Applied Genetic Technologies Corporation since June 30, 2014. He serves on the Boards of Imagen Biotech Inc. He served as Director of Allocure, Inc. Eyetech Pharmaceuticals, Inc., and Neurotech Pharmaceuticals Inc. He served as the Chairman of Lux Biosciences Inc. He has been an Director of Sound Pharmaceuticals, Inc. since October 12, 2017. Dr. Guyer served as Director of Link Medicine Corporation and Neovista, Inc. He served as a Non-Executive Director of Optos plc from May 5, 2006 to April 1, 2009. He served as a Director at Eyetech. He served as Director of Oldtech, Inc. since February 2000. He served as Director of Lux Biosciences, Inc. since July 2006. He served as Director of Danube Pharmaceuticals, Inc since June 2008. He served as the Chairman of NYU Elaine A. and Kenneth G. Langone Medical Center. He was the Study Co-Chairman of the Pharmacological Therapy for Macular Degeneration Study Group. Dr. Guyer served as a Professor and Chairman of the Ophthalmology Department at the New York University School of Medicine. He was Professor and Chairman of the department of ophthalmology at the NYU School of Medicine. He is an author of more than 100 publications. He is an internationally recognized authority on macular diseases, particularly the use of anti-angiogenic drugs for the treatment of AMD and Diabetic Macular Edema (DME). He was ophthalmology resident at the Wilmer Eye Institute at Johns Hopkins Hospital and did his fellowship training in retinal surgery at the Massachusetts Eye and Ear Infirmary, where he was a Heed-Knapp Fellow. He completed his ophthalmology residency at the Wilmer Ophthalmological Institute at Johns Hopkins Hospital and a retinal fellowship at the Massachusetts Eye and Ear Infirmary at Harvard Medical School. Dr. Guyer received an M.D. from the Johns Hopkins University School of Medicine and a B.Sc. degree from Yale College. Dr. David R. Guyer, M.D., served as Advisor of Sound Pharmaceuticals, Inc. since April 13, 2017 until October 12, 2017. Dr. Guyer is a Consultant on Ophthalmic Products to more than 12 different pharmaceutical companies. He has been the Executive Chairman at Ophthotech Corporation since July 1, 2017 and has been its Executive Director since January 2007. He is a Co-Founder and Executive Chairman of Imagen Biotech, Inc. He Co-Founded Ophthotech Corporation and served as its Chief Executive Officer from April 2013 to July 1, 2017. He served as Scientific Advisor of Iconic Therapeutics Inc. He was a Venture Partner of SV Health Investors, LLC, which he joined in May 2006. He was a Partner at SV Health Investors, LLC and is focused on biotechnology. He co-founded Eyetech Pharmaceuticals Inc. and served as its Chief Executive Officer. Dr. Guyer was a Co-Founder of Oldtech Inc. and served as its Chief Executive Officer since February 2000. He served as a Consultant to management and the Board at OSI Pharmaceuticals, where he provides specialist input in ophthalmology and retinal disease. He served as Chief Executive Officer (OSI) Eyetech at OSI Pharmaceuticals Inc. from November 2005 to May 2006. He served as an Executive Vice President at OSI Pharmaceuticals Inc. from November 14, 2005 to May 2006. He serves as the Chairman of PanOptica Inc. He served as Chairman of Ophthotech Corporation since January 2007 until July 1, 2017. He served as Chairman at New York University College of Medicine. He served as the Chairman of Danube Pharmaceuticals Inc. since June 2008. He has been a Non-Executive Director of ThromboGenics NV since December 20, 2013 and Applied Genetic Technologies Corporation since June 30, 2014. He serves on the Boards of Imagen Biotech Inc. He served as Director of Allocure, Inc. Eyetech Pharmaceuticals, Inc., and Neurotech Pharmaceuticals Inc. He served as the Chairman of Lux Biosciences Inc. He has been an Director of Sound Pharmaceuticals, Inc. since October 12, 2017. Dr. Guyer served as Director of Link Medicine Corporation and Neovista, Inc. He served as a Non-Executive Director of Optos plc from May 5, 2006 to April 1, 2009. He served as a Director at Eyetech. He served as Director of Oldtech, Inc. since February 2000. He served as Director of Lux Biosciences, Inc. since July 2006. He served as Director of Danube Pharmaceuticals, Inc since June 2008. He served as the Chairman of NYU Elaine A. and Kenneth G. Langone Medical Center. He was the Study Co-Chairman of the Pharmacological Therapy for Macular Degeneration Study Group. Dr. Guyer served as a Professor and Chairman of the Ophthalmology Department at the New York University School of Medicine. He was Professor and Chairman of the department of ophthalmology at the NYU School of Medicine. He is an author of more than 100 publications. He is an internationally recognized authority on macular diseases, particularly the use of anti-angiogenic drugs for the treatment of AMD and Diabetic Macular Edema (DME). He was ophthalmology resident at the Wilmer Eye Institute at Johns Hopkins Hospital and did his fellowship training in retinal surgery at the Massachusetts Eye and Ear Infirmary, where he was a Heed-Knapp Fellow. He completed his ophthalmology residency at the Wilmer Ophthalmological Institute at Johns Hopkins Hospital and a retinal fellowship at the Massachusetts Eye and Ear Infirmary at Harvard Medical School. Dr. Guyer received an M.D. from the Johns Hopkins University School of Medicine and a B.Sc. degree from Yale College.

Eye Diseases and Disorders